Sanofi Partners With Maze On Oral Pompe Drug

 
• By Jessica Merrill

Deal Snapshot: Maze gets $150m up front in cash and equity in exchange for development and commercial rights to a GYS1 program for Pompe disease.

pills
Sanofi licensed a potential oral drug for Pompe disease. • Source: Shutterstock

Who: Sanofi and Maze Therapeutics

What: Sanofi gains worldwide development and commercial rights to Maze’s glycogen synthase 1 (GYS1) program, including MZE001, in early

More from Deals

More from Business